JVP and AstraZeneca Launch Joint Digital-Health Initiative


The top ten initiatives to join the initiative PlayBeyondBio will supercharge their digital health startup, enjoying guidance from AstraZeneca experts in areas of development, regulation and sales, as well as JVP experts on building global companies, securing investments, data access and recruiting assistance along with the support and mentorship of Microsoft for Startups leaders.

Application Deadline: March 11th, 2020


Jerusalem, February 24, 2020: Internationally renowned VC JVP, and AstraZeneca, the world’s leading pharmaceutical company, along with Israel Initiative have launched the call for application for PlayBeyondBio, designed to attract, screen, develop and promote innovative start-ups in the digital health field.

PlayBeyondBio is a business platform where the world’s leading ecosystem players join forces to supercharge digital health startups, connecting the entrepreneur, the investor and the potential customer, building internationally disruptive companies. This first of its kind strategic partnership between AstraZeneca, JVP and Israel Initiative is in collaboration with Maccabitech Healthcare Research and Innovation Institute, Morris Kahn, the Sagol Fund, Shaare-Tzedek Hospital and Microsoft for Startup.

The Call for Application is geared towards digital healthcare start-ups looking the be one of the 10 select startups in this unique 6-month program; the fast-track towards promoting each company’s global market growth.

Once a part of PlayBeyondBio, the selected startups will be assigned a team of mentors from strategic partners who will help define their vision, their potential markets and messaging. Startups will enjoy exclusive guidance from AstraZeneca experts in areas of development, regulation and sales, as well as from JVP experts on building global companies, securing investments, and access to databases. Additionally, startups will be able to utilize the enormous professional network of JVP and AstraZeneca along with support and mentorship of Microsoft for Startups leaders. This process will dramatically increase these startups’ chances to become groundbreaking companies, in line with actual market needs.

PlayBeyondBio will identify technological answers to the most pressing issues and challenges that the industry currently copes with. Ranging from diagnostic to patient well-being the program will focus on various clinical areas, including cancer, lung disease, cardiovascular disease and metabolic disease, as well as non-clinically technological solutions in order to identify and develop breakthrough technological solutions. Following PlayBeyondBio’s unique model, the platform’s strategic partners will be involved in all stages of the process, from the screening and recruiting phase, through product development and adaptation to global market needs, product testing in the “real environment”, and the possibility of commercial agreements and providing funding during and after the program.

Applications to PlayBeyondBio will close on March 11th 2020. The screening process will be demand-driven as defined by the strategic partners in cooperation with JVP. Selection will be based on the potential proof of value of the suggested technology and solution, and the magnitude of the need the product is addressing.

“PlayBeyondBio is revolutionary in the development of Israeli digital healthcare startups that have the potential to change rules of the game worldwide,” says Erel Margalit, Founder, and Chairman of JVP, “We connect the entrepenuer, the investor, the customer and the healthcare system in the earliest stage, within one ecosystem. Israel now has the opportunity to become a global leader in digital healthcare innovation, and Israeli entrepreneurs have the ability to lead this revolution. The disruptiveness of Israeli technologies combined with the knowledge, expertise and challenges presented by AstraZeneca, the leading international pharma company, along with other partners such as Microsoft, Israel Initiative, Maccabi, and Israel’s leading hospitals present significant infrastructure for building groundbreaking, successful, deeply rooted companies; The next big thing in digital health.”

Ohad Goldberg, CEO of AstraZeneca Israel: “AstraZeneca’s local representatives have been working for over a decade to provide medicine and investment in clinical research in Israel, and we are proud to launch BeyondBio, a unique program created as part of the recognition of Israel as an emerging force in digital innovation and health. AstraZeneca, along with the strategic partners of the program will support the development of medical solutions that provide the healthcare system with better tools to address patients in Israel and around the world. “

About Jerusalem Venture Partners (JVP)

Jerusalem Venture Partners (JVP), was founded and led by Dr. Erel Margalit, is an internationally renowned venture capital fund. JVP has to date raised $1.4 billion across 9 funds, and has been listed numerous times by Preqin, and other rankings, as one of the top-ten consistently performing VC firms worldwide. JVP has built over 140 companies, leveraging a broad network of partners and market expertise to help companies become global market leaders. JVP has been chosen by Ney York City and EDC to lead the cyber security cyber huh in NYC. Among the pioneering firms of the Israeli venture capital industry, JVP has been instrumental in building some of the largest companies out of Israel, facilitating 12 Initial Public Offerings on NASDAQ including CyberArk Software (NASDAQ: CYBR, $4.7 billion mkt. cap.), QLIK Technologies (NASDAQ: QLIK, then $4 billion mkt. cap.) and Cogent Communications (NASDAQ: CCOI, $3 billion mkt. cap.) and more https://www.jvpvc.com/


About AstraZeneca

AstraZeneca is the leading global pharmaceutical, innovation-driven company that initiates and promotes research, development and the distribution of innovative prescription pharmaceuticals. The company operates in a number of core areas that include cancer, cardiovascular, metabolic and respiratory diseases for which the company has developed breakthrough drugs. The company operates in over 100 countries worldwide, and AstraZeneca Israel was established in 2007 as the official representative of the international company in the country. AstraZeneca Israel invests in research, development and medical treatment, promotes and encourages clinical trials and works together with medical organizations in an effort to strengthen the healthcare services provided for the benefit of the greater society. https://www.astrazeneca.com/



Back to Press releases